Cancer Biomarkers in Body Fluids : Biomarkers in Circulation /: Biomarkers in Circulation. ([2017])
- Record Type:
- Book
- Title:
- Cancer Biomarkers in Body Fluids : Biomarkers in Circulation /: Biomarkers in Circulation. ([2017])
- Main Title:
- Cancer Biomarkers in Body Fluids : Biomarkers in Circulation
- Further Information:
- Note: Gabriel D. Dakubo.
- Authors:
- Dakubo, Gabriel D
- Contents:
- Preface; Contents; About the Author; Chapter 1: Melanoma Biomarkers in Circulation; Key Topics; 1.1 Introduction; 1.2 Screening Recommendations for Melanoma; 1.3 Molecular Pathology of Melanoma; 1.3.1 BRAF Mutations in Melanoma; 1.3.2 RAS Mutations in Melanoma; 1.3.3 Alterations in Cell Cycle Control Genes in Melanoma; 1.3.4 TP53 Mutations in Melanoma; 1.3.5 KIT Mutations in Melanoma; 1.3.6 MITF Mutations in Melanoma; 1.3.7 PI3K Pathway Alterations in Melanoma; 1.3.8 Molecular Subtypes of Melanoma; 1.3.9 Molecular Progression Model of Melanoma; 1.4 Circulating Melanoma Biomarkers. 1.4.1 Circulating Melanoma Cell-Free Nucleic Acid Biomarkers1.4.2 Circulating Melanoma Epigenetic Biomarkers; 1.4.3 Circulating Melanoma Genetic Biomarkers; 1.4.3.1 Mutations as Circulating Melanoma Biomarkers; 1.4.3.2 Circulating MSA as Melanoma Biomarkers; 1.4.4 Circulating Melanoma Coding RNA Biomarkers; 1.4.5 Circulating Melanoma Noncoding RNA Biomarkers; 1.4.6 Circulating Melanoma Protein Biomarkers; 1.4.6.1 Serum S100beta as Melanoma Biomarker; 1.4.6.2 Serum LDH as Melanoma Biomarker; 1.4.6.3 Serum MIA as Melanoma Biomarker; 1.4.6.4 Serum VEGF as Melanoma Biomarker. 1.4.6.5 Serum Levodopa to l-Tyrosine Ratio as Melanoma Biomarker1.4.6.6 Serum Cysteinyldopa as Melanoma Biomarker; 1.4.6.7 Serum Autoantibodies as Melanoma Biomarkers; 1.4.6.8 Circulating Melanoma Proteomic Biomarkers; 1.4.7 Circulating Melanoma Cells; 1.4.7.1 Molecular Approaches to CMCs; 1.4.7.2 CMCs in Advanced Stage III and IVPreface; Contents; About the Author; Chapter 1: Melanoma Biomarkers in Circulation; Key Topics; 1.1 Introduction; 1.2 Screening Recommendations for Melanoma; 1.3 Molecular Pathology of Melanoma; 1.3.1 BRAF Mutations in Melanoma; 1.3.2 RAS Mutations in Melanoma; 1.3.3 Alterations in Cell Cycle Control Genes in Melanoma; 1.3.4 TP53 Mutations in Melanoma; 1.3.5 KIT Mutations in Melanoma; 1.3.6 MITF Mutations in Melanoma; 1.3.7 PI3K Pathway Alterations in Melanoma; 1.3.8 Molecular Subtypes of Melanoma; 1.3.9 Molecular Progression Model of Melanoma; 1.4 Circulating Melanoma Biomarkers. 1.4.1 Circulating Melanoma Cell-Free Nucleic Acid Biomarkers1.4.2 Circulating Melanoma Epigenetic Biomarkers; 1.4.3 Circulating Melanoma Genetic Biomarkers; 1.4.3.1 Mutations as Circulating Melanoma Biomarkers; 1.4.3.2 Circulating MSA as Melanoma Biomarkers; 1.4.4 Circulating Melanoma Coding RNA Biomarkers; 1.4.5 Circulating Melanoma Noncoding RNA Biomarkers; 1.4.6 Circulating Melanoma Protein Biomarkers; 1.4.6.1 Serum S100beta as Melanoma Biomarker; 1.4.6.2 Serum LDH as Melanoma Biomarker; 1.4.6.3 Serum MIA as Melanoma Biomarker; 1.4.6.4 Serum VEGF as Melanoma Biomarker. 1.4.6.5 Serum Levodopa to l-Tyrosine Ratio as Melanoma Biomarker1.4.6.6 Serum Cysteinyldopa as Melanoma Biomarker; 1.4.6.7 Serum Autoantibodies as Melanoma Biomarkers; 1.4.6.8 Circulating Melanoma Proteomic Biomarkers; 1.4.7 Circulating Melanoma Cells; 1.4.7.1 Molecular Approaches to CMCs; 1.4.7.2 CMCs in Advanced Stage III and IV Melanoma; 1.4.7.3 CMCs in Uveal Melanoma; 1.4.8 Melanoma Extracellular Vesicles; 1.4.9 Summary; References; Chapter 2: Head and Neck Cancer Biomarkers in Circulation; Key Topics; 2.1 Introduction; 2.2 Screening Recommendations for HNC. 2.3 The Need for Noninvasive Screening Tests for HNC2.4 Molecular Pathology of HNC; 2.4.1 Molecular Classification of HNC; 2.4.2 Molecular Pathology of HPV-Positive HNC; 2.4.3 Specific Genetic Alterations in HNC; 2.4.3.1 EGFR Alterations in HNC; 2.4.3.2 TGFbeta Pathway Alterations in HNC; 2.4.3.3 PI3K/AKT Pathway Alterations in HNC; 2.4.3.4 TP53 Alterations in HNC; 2.4.3.5 Cell Cycle Gene Alterations in HNC; 2.4.3.6 MET Alterations in HNC; 2.4.3.7 Telomere Alterations in HNC; 2.5 Circulating HNC Biomarkers; 2.5.1 Circulating Cell-Free Nucleic Acids as HNC Biomarkers. 2.5.2 Circulating HNC Epigenetic Biomarkers2.5.3 Circulating HNC Noncoding RNA Biomarkers; 2.5.3.1 Oncomirs and Tumor Suppressormirs in HNC; 2.5.3.2 Circulating HNC miRNA Biomarkers; 2.5.4 Circulating HNC Serum Protein Biomarkers; 2.5.5 Circulating HNC Cells; 2.5.5.1 Methodologies for CHNCC Analysis; 2.5.5.2 CHNCCs as Staging Biomarkers; 2.5.5.3 CHNCCs as Prognostic Biomarkers; 2.5.5.4 CHNCCs as Predictive Biomarkers; 2.5.5.5 Induction of CHNCCs by Clinical Interventions; 2.5.6 Circulating HPV-Positive HNC Biomarkers; 2.5.7 HNC Extracellular Vesicles; 2.6 Nasopharyngeal Carcinoma. … (more)
- Publisher Details:
- Cham, Switzerland : Springer
- Publication Date:
- 2017
- Extent:
- 1 online resource (xix, 519 pages), illustrations (some color)
- Subjects:
- 616.99/40756
Medicine
Cancer -- Molecular diagnosis
Cancer -- Genetic aspects
Biochemical markers
Biomarkers, Tumor
HEALTH & FITNESS -- Diseases -- General
MEDICAL -- Clinical Medicine
MEDICAL -- Diseases
MEDICAL -- Evidence-Based Medicine
MEDICAL -- Internal Medicine
Biochemical markers
Cancer -- Genetic aspects
Cancer -- Molecular diagnosis
Biomedicine
Human Genetics
Oncology
Cancer Research
Medical -- Oncology
Oncology
Human genetics
Oncology
Oncology
Medical -- Genetics
Medical genetics
Electronic books
Electronic book - Languages:
- English
- ISBNs:
- 3319483609
9783319483603 - Related ISBNs:
- 9783319483597
3319015796
3319483595 - Notes:
- Note: Includes bibliographical references and index.
Note: Online resource; title from digital title page (viewed on December 19, 2016). - Access Rights:
- Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
- Access Usage:
- Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD.DS.370303
- Ingest File:
- 01_355.xml